Mar 21, 2022

Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’

Posted by in categories: biotech/medical, mobile phones

Ever since last year’s annual American Association of Cancer Research (AACR) meeting, Volastra’s phone has been “ringing off the hook,” according to CEO Charles Hugh-Jones, M.D. | Two years since its inception, Volastra Therapeutics is partnering with Bristol Myers Squibb for up to three oncology targets focused on chromosomal instability, a deal that could exceed $1.1 billion should the assets hit milestones.

Comments are closed.